

Interferon Alfa-2b Suppresses Proliferative Scar (Hypertrophic Scar and Keloid) Fibroblast Contraction *in Vitro*

Keiichiro SAHARA and Takahiko MORIGUCHI

*Department of Plastic and Reconstructive Surgery,
Kawasaki Medical School, Kurashiki 701-01, Japan*

Accepted for publication on November 19, 1996

ABSTRACT. Purpose: An *in vitro* model of dermis was reconstituted by introducing fibroblasts on type I collagen gel. The model was maintained in culture to investigate the cellular behaviors of human dermal fibroblasts and proliferative scar fibroblasts. Increased fibroblast activity and collagen production have been observed frequently in proliferative scars. Previous studies have demonstrated that interferons suppress collagen production by means of normal, hypertrophic scars, and keloid-derived fibroblasts. We used the FPCL to evaluate the effect of interferon on fibroblasts harvested from normal human skin, human hypertrophic scars, and keloid tissues. Methods: Human recombinant interferon alfa-2b (IFN α -2b: 1000 IU/ml) was added to the culture media. The collagen gel was overlaid with 1×10^5 fibroblast cells. Results: The keloid FPCL showed the highest contraction. Contraction in all the groups appeared to be suppressed by IFN α -2b during the first 72 hours of the experiment ($p < 0.05$). Conclusion: The contractile properties of fibroblasts taken from normal human skin, hypertrophic scars, and keloids in this *in vitro* study were suppressed by IFN α -2b. The contraction obtained in the interferon-treated keloid group was similar to the contraction obtained in the untreated normal skin. These findings suggest that IFN α -2b may be beneficial for the treatment of proliferative scars.

Key words: FPCL — hypertrophic scar — keloid — IFN α -2b

Fibrosis is a normal reparative process that occurs after tissue injury. It is characterized histologically by fibroblast hyperplasia and increased collagen deposition. In addition, contraction of the fibrotic mass may occur and may be required for normal wound healing. Contraction can also lead to distortion of normal tissue architecture and contribute to organ dysfunction in pathologic fibrosis.¹⁾ After tissue injury, resident fibroblasts undergo a metabolic activation and exhibit increased growth and synthetic rates to repair injured tissue. Activation likely occurs when resident fibroblasts are exposed to fibroblast-stimulatory factors/cytokines during the early inflammation-associated phase of the fibrotic response.²⁻⁴⁾

Hypertrophic scars and keloid tissues are examples of fibroblast proliferation and overabundant collagen deposition in healed wounds.⁵⁾ Collagen deposition has not been shown to be the result of decreased collagenase activity in keloids.^{6,7)} Instead, it has been suggested that the effectiveness of collagenase activity may be diminished. The biological and clinical differences between hypertrophic scars and keloids have still not been clearly established.^{8,9)} Currently, there is no safe,

systemic, preventive treatment for regulating fibroblast proliferation, collagen production, and scar contraction in proliferative diseases.

Interferons are important soluble products of cells involved in inflammatory reactions and are capable of influencing the proliferation of various fibroblastic cell lines.¹⁰⁻¹³ Interferon alfa-2b (IFN α -2b) inhibits the proliferation and certain biosynthetic activities of fibroblasts derived from a variety of tumor and transformed cell lines, as well as from normal skin.^{10,13} Investigators have suggested that interferons may play an important role in the regulation and, possibly, the termination of fibrosis by suppressing persistently activated fibroblast functions.^{11,12}

There are no satisfactory *in vivo* systems available for the study of proliferative scars. The observation that fibroblasts that are cultured in collagen gel cause the gel to contract made it possible to study fibroblast behavior in a well-controlled environment.^{14,15} This *in vitro* fibroblast-populated collagen lattice (FPCL) system has been used for wound healing studies and has been prepared as a possible replacement for damaged skin.¹⁶ The ability of fibroblasts to contract collagen gels is one of the specific fibroblast functions that might also occur *in vivo*. Some authors¹⁷ consider studies made in FPCLs to be more physiologic than those made on monolayer cultures.

In this study with the FPCL model, we evaluated the effect of IFN α -2b on fibroblasts harvested from normal skin, hypertrophic scars, and keloids.

MATERIALS AND METHODS

Materials and culture conditions

Primary fibroblast cultures were established from six hypertrophic scars, four keloids, and eight normal skin samples obtained by surgical procedures (Table 1). The specimens were sectioned into 1 to 2 mm segments, placed into tissue flasks with Dulbecco's modified Eagle's medium (DMEM) and penicillin (100 IU/ml ;

TABLE 1. Cases of proliferative scars

Case	Age · Sex	Scar	Site	Cause	Passage
1	14y M	HTS	abdomen	ope.	2y5m
2	21y F	HTS	knee	trauma	1y2m
3	29y F	HTS	abdomen	ope.	1y8m
4	10y M	HTS	chest	trauma	3y5m
5	49y M	HTS	elbow	trauma	1y5m
6	36y F	HTS	abdomen	ope.	2y2m
7	38y F	KL	shoulder	trauma	10y5m
8	37y F	KL	abdomen	ope.	8y5m
9	25y F	KL	ear	pierce	2y5m
10	24y F	KL	abdomen	ope.	5y5m

HTS : Hypertrophic scar

KL : Keloid

ope : operation

passage : period from injury to scar revision

y : year, m : month

Gibco Labo, Grand Island, NY, USA), streptomycin (100 μ g/ml; Gibco), and 10% fetal bovine serum (FBS; HyClone Labo, Logan, Utah, USA). Then they were incubated at 37°C in a humidified atmosphere of 5% carbon dioxide. The culture medium was renewed every three days. Confluent primary cultures were trypsinized and subcultured. The cell cultures were studied during passages five through seven.

Interferon treatment

Subconfluent fibroblast cultures were arranged by placing 1×10^4 freshly trypsinized fibroblasts, contained in 2 ml of DMEM with 10% FBS, into triplicate wells with or without IFN α -2b (Schering Co, Kenilworth, NJ, USA). Human recombinant IFN α -2b (1000 IU/ml) was present in the culture media for 14 days until the confluence was reached. The culture medium was renewed every three days with or without IFN.

Preparation of collagen lattice

The collagen lattice was prepared as previously described with Type I collagen (derived from porcine tendon, Nitta Gelatine Co, Tokyo, Japan)^{14,18,19}. Then, 1 ml of this mixture was poured into a 35-mm bacteriological dish (Falcon Co, Kanagawa, Japan). The final collagen concentration was 1.5 mg/ml.

Measurement of gel contraction

The cells were collected by trypsinization and centrifugation at day 14 and resuspended in culture medium. Cell numbers were adjusted to 1×10^5 cells/ml. Then we overlaid 1 ml of this solution on the collagen gels and incubated it at 37°C in a humidified atmosphere of 5% carbon dioxide.

The amount of gel contraction was measured at 4, 8, 12, 24, 48, and 72 hours after incubation. Acetate overlays were used for tracing the perimeters of the gels. The traced areas were digitally measured with the aid of a personal computer (Apple Japan, Inc, Tokyo, Japan).

Statistical analysis

Repeated collagen gel area measurements were transformed to reflect the percentage of remaining area over time. These data underwent analysis of variance; the significance of the differences among the overall group means was tested by Duncan's range test ($p < 0.05$).

RESULTS

FPCLs containing normal human skin, hypertrophic scar, and keloid fibroblasts showed continuous reduction in gel areas for 72 hours (Fig 1). The overall group means differed significantly among the untreated groups ($p < 0.05$).

Reduction of the gel area was highest in the keloid group. FPCLs containing keloid fibroblasts contracted to $32.1\% \pm 3.8\%$ of the original area in 24 hours and $28.3\% \pm 3.6\%$ in 72 hours (67.9% and 71.7% contraction, respectively). FPCLs containing hypertrophic scars and normal skin fibroblasts contracted to $39.0\% \pm 1.9\%$ and $48.1\% \pm 2.8\%$ of the original areas in 24 hours (61.0% and 51.9% contraction), and $33.4\% \pm 4.7\%$ and $40.3\% \pm 5.0\%$ of the original areas in 72 hours (66.6% and 59.7% contraction).




Fig 1. Contraction of collagen lattices by human dermal fibroblasts (○) and fibroblasts isolated from hypertrophic scar (△) and keloid (□). Contraction curves were significantly different ($p < 0.05$). FPCL: Fibroblast-populated collagen lattice




Fig 2. Contraction of collagen lattices by all IFN- α -2b treated groups, human dermal fibroblasts (●), hypertrophic scar derived fibroblasts (▲), and keloid derived fibroblasts (■). Contraction curves were significantly different among IFN-treated groups ($p < 0.05$). FPCL: Fibroblast-populated collagen lattice

Treatment of fibroblasts with IFN α -2b reduced contraction in all the groups by 9% to 17% (Fig 2). FPCLs containing keloid fibroblasts contracted to $48.0\% \pm 1.0\%$ of the original area in 24 hours and $37.4\% \pm 0.7\%$ in 72 hours (52.0% and 62.6% contraction, respectively). FPCLs containing hypertrophic scars and normal skin fibroblasts contracted to $55.1\% \pm 3.6\%$ and $65.3\% \pm 3.7\%$ of the original areas in 24 hours (44.9% and 34.7%), $43.1\% \pm 1.9\%$ and $51.4\% \pm 2.0\%$ in 72 hours (56.9% and 48.6% contraction). The contraction curves were also differed significantly among the interferon-treated groups ($p < 0.05$). However, there was no significant difference in the reduction of contraction by interferon among the groups (Fig 3).

The contraction obtained in the interferon-treated keloid group did not differ from that obtained in the untreated normal skin FPCL group (Fig 4). The overall mean collagen gel areas for these groups were similar.




Fig 3. IFN-induced reduction of FPCL contraction was not significant among groups ($p > 0.05$).
FPCL: Fibroblast-populated collagen lattice




Fig 4. IFN-treated (IFN α -2b, 1000 IU/ml) keloid fibroblast (■) showed similar contraction with normal human dermal fibroblast group (○), ($p < 0.05$).

DISCUSSION

Abnormal fibrosis is not unique to keloid formation and is the predominant pathologic change in other serious cutaneous and systemic diseases, including scleroderma, chronic graft-versus-host disease, pulmonary fibrosis, and liver cirrhosis. Excessive deposition of collagen is a major pathologic feature in several fibrotic diseases that can affect the skin or a variety of internal organs. In many of these conditions, an increase in collagen synthesis may not be the primary event of the disease process. Nevertheless, the excessive accumulation of collagen has major consequences in terms of the structure and function of the affected organs.²⁰⁾ Fibroblasts are responsible for the production and maintenance of the connective tissue matrix by synthesis and degradation of its components. This balance of synthesis and degradation is only transiently altered during normal repair processes, as it is in wound healing, but abnormalities in matrix component metabolism may be responsible for the excessive fibrosis that occurs in keloids and hypertrophic scars.^{13,21)} The overabundant deposition of collagen in keloids may result from decreased collagen degradation. Yet, collagenase activity has been reported to be normal^{6,7)} or even increased.⁸⁾ In addition, collagen degradation has been reported to be normal in tissue explants⁶⁾ and keloid fibroblast cultures.⁹⁾ Thus, it has been suggested that a pharmacologic approach that could arrest collagen deposition in the tissues would be beneficial to patients with clinical fibrotic diseases.²²⁻²⁴⁾

In our study, the untreated keloid FPCL showed the greatest contraction as compared with both hypertrophic scar and normal skin control groups. Interferon treatment suppressed keloid, hypertrophic scar, and normal skin FPCL contractions. The suppression of the contractions was similar in all the groups. The extent of contraction obtained in the interferon-treated keloid group resembled that of the untreated normal skin FPCL contraction. These findings suggest that interferon normalizes the behavior of keloid fibroblasts in an FPCL system.

The mechanism of fibroblast-mediated collagen gel contraction is poorly understood and is still controversial.²⁵⁾ Previous studies on the contraction of collagen gels have led to the suggestion that this process approximates cell-matrix interactions *in vivo* and may be an important mechanism of connective tissue morphogenesis.^{14,26-35)} Gillery *et al*³²⁾ suggested that the contraction of collagen lattices by human skin fibroblasts appears to be a complex phenomenon that requires at least two conditions: the presence of macromolecular serum components and protein synthesis by the cells.³²⁾ Although interferons are only transient inhibitors of normal fibroblast functions, they do act as persistent deactivators of at least one activated fibroblast function.¹¹⁾ It is known that protein synthesis is inhibited by interferon in culture.¹⁰⁾ We do not know whether the effect of interferon in our experiment was due to persistent suppression of protein synthesis because protein synthesis was not measured in the FPCL. In addition, contraction of the *in vitro* collagen matrix is related to the movement of fibroblasts in the gel, not to renewed collagen synthesis. It is possible that the synthesis of fibronectin, which probably aids fibroblast-mediated collagen gel contraction,²⁵⁾ is reduced by the action of interferon.

Abnormal scar contraction is one of the factors in progression of the fibrotic process. Because contraction is suppressed in the FPCL by interferon, this may be considered to be a favorable effect. Keloids and hypertrophic scars may benefit from interferon treatment, regardless of the mechanisms leading to aberrant fibroblast activation. It is noteworthy that the reduction of contraction in each group was similarly affected by interferon. This finding also supports the concept of general *in vivo* fibroblast deactivation by interferons, as has been reported in previous studies.^{11,36,37)}

In conclusion, our findings support the potential role for IFN α -2b as a down-regulatory growth factor for the treatment of proliferative scars. Findings also suggest that IFN α -2b may delay wound healing. It is possible that this *in vitro* model system can be used to determine the mechanism of this regulatory effect on wound repair. Further studies involving the investigation of the keloid fibroblasts of additional patients are necessary.

ACKNOWLEDGMENTS

This work was supported in part by a Research Project Grant from Kawasaki Medical School (No.7-711).

REFERENCES

- 1) Prockop DJ, Kivirikko KI, Tuderman L, Guzman NA : The biosynthesis of collagen and its disorders. *N Engl J Med* **301** : 13-23, 1979
- 2) Korotzer TI, Clagett JA, Kolb WP, Page RC : Complement-dependent induction of DNA synthesis and proliferation of human diploid fibroblast. *J Cell Physiol* **105** : 503-512, 1980
- 3) Pohjanpelto P : Stimulation of DNA synthesis in human fibroblasts by thrombin. *J Cell*

- Physiol **95** : 189-194, 1978
- 4) Clark R A F : Cutaneous tissue repair : Basic biological considerations. J Am Acad Dermatol **13** : 701-725, 1985
 - 5) Cohen IK, Keiser HR, Sjoerdsma A : Collagen synthesis in human keloid and hypertrophic scar. Surg Forum **22** : 488-489, 1971
 - 6) Milsom JP, Craig RDP : Collagen degradation in cultured keloid and hypertrophic scar tissue. Br J Dermatol **89** : 635-643, 1973
 - 7) McCoy BJ, Cohen IK : Collagenase in keloid biopsies and fibroblasts. Connect Tissue Res **9** : 181-185, 1982
 - 8) Cohen IK, Diegelmann RF, Keiser HR : Collagen metabolism in keloid and hypertrophic scar. In The ultrastructure of collagen, ed. by Thomas C C. 1973, pp 199-212
 - 9) Diegelmann RF, Cohen IK, McCoy BJ : Growth kinetics and collagen synthesis of normal scar, and keloid fibroblasts *in vitro*. J Cell Physiol **98** : 341-346, 1979
 - 10) Duncan MR, Berman B : Gamma interferon is the lymphokine and beta interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation. J Exp Med **162** : 516-527, 1985
 - 11) Duncan MR, Berman B : Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons. J Clin Invest **79** : 1318-1324, 1987
 - 12) Rosenbloom J, Feldman G, Freundlich B, Jiminez S : Transcriptional control of human diploid fibroblast collagen synthesis by gamma-interferon. Biochem Biophys Res Commun **123** : 365-372, 1984
 - 13) Berman B, Duncan MR : Short-term keloid treatment *in vivo* with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production *in vitro*. J Am Acad Dermatol **21** : 694-702, 1989
 - 14) Bell E, Ivarsson B, Merrill C : Production of a tissue-like structure by contraction of collagen lattice by human fibroblasts of different proliferative potential *in vitro*. Proc Natl Acad Sci USA **76** : 1274-1278, 1979
 - 15) Bellows CG, Melcher AH, Aubin JE : Contraction and organization of collagen gels by cells cultured from periodontal ligament, gingiva and bone suggest functional differences between cell types. J Cell Sci **50** : 299-314, 1981
 - 16) Bell E, Sher S, Hull B, Merrill C, Rosen S, Chamson A, Asselineau D, Dubertet L, Coulomb B, Lapiere C, Nusgens B, Neveux Y : The reconstitution of living skin. J Invest Dermatol **81** : 2s-10s, 1983
 - 17) Coulomb B, Dubertet L, Merrill C, Touraine R, Bell E : The collagen lattice : A model for studying the physiology, biosynthetic function and pharmacology of the skin. Br J Dermatol **111** Suppl **27** : 83-87, 1984
 - 18) Abdullah KM, Phillips LG, Huang F, Ko F, Hayward PG, Robson MC : Diabetic fibroblasts contract faster. Surg Forum **42** : 650-651, 1991
 - 19) Elsdale T, Bard J : Collagen substrata for studies on cell behavior. J Cell Biol **54** : 626-637, 1972
 - 20) Sahara K, Kucukcelebi A, Ko F, Phillips LG, Robson MC : Suppression of *in vitro* proliferative scar fibroblast contraction by interferon alfa-2b. WOUND REP REG **1** : 22-27, 1993
 - 21) Berman B, Duncan MR : Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphoea skin and their production of collagen, glycosaminoglycans and fibronectin. Br J Dermatol **123** : 339-346, 1990
 - 22) Uitto J, Tan EML, Ryhanen L : Inhibition of collagen accumulation in fibrotic processes : review of pharmacologic agents and new approaches with amino acids and their analogies. J Invest Dermatol **79** : 113-120, 1982
 - 23) Uitto J, Ryhanen L, Tan EML, Oikarinen AI, Zaragoza EJ : Pharmacological inhibition of excessive collagen deposition in fibrotic diseases. Fed Proc **43** : 2815-2820, 1984
 - 24) Sasaki T, Majamaa K, Uitto J : Reduction of collagen production in keloid fibroblast cultured by Ethyl 1-3, 4-dihydroxybenzoate. J Biol Chem **262** : 9397-9403, 1987
 - 25) Asaga H, Kikuchi S, Yoshizato K : Collagen gel contraction by fibroblasts requires cellular fibronectin but not plasma fibronectin. Exp Cell Res **193** : 167-174, 1991
 - 26) Tomasek JJ, Hay ED, Fujiwara K : Collagen modulates cell shape and cytoskeleton of embryonic corneal and fibroma fibroblasts : distribution of actin, alpha-actin, and myosin. Dev Biol **92** : 107-122, 1982
 - 27) Kleinman HK, Klebe RJ, Martin GR : Role of collagenous matrice in the adhesion and growth of cells. J Cell Biol **88** : 473-485, 1981

- 28) Nishiyama T, Tominaga N, Nakajima K, Hayashi T : Quantitative evaluation of the factors affecting the process of fibroblast-mediated collage gel contraction by separating the process into three phases. *Collagen Re Res* **8** : 259-273, 1988
- 29) Stopak D, Harris A : Connective tissue morphogenesis by fibroblast traction. *Dev Biol* **90** : 383-398, 1982
- 30) Guidry C, Grinnell F : Heparin modulates the organization of hydrated collagen gels and inhibits gel contraction by fibroblasts. *J Cell Biol* **104** : 1097-1103, 1987
- 31) Ehrlich HP, White ME : Effects of increased concentrations of prostaglandin E levels with epidermolysis bullosa dystrophica recessive fibroblasts within a populated collagen lattice. *J Invest Dermatol* **81** : 572-575, 1983
- 32) Gillery P, Maquart F, Borel J : Fibronectin dependence of the contraction of collagen lattice by human skin fibroblasts. *Exp Cell Res* **167** : 29-37, 1986
- 33) Adams LW, Priestley GC : Contraction of collagen lattice by skin fibroblasts from dystrophic recessive epidermolysis bullosa and other dermatoses. *J Invest Dermatol* **87** : 544-546, 1986
- 34) Van Story-Lewis PE, Tenenbaum HC : Glucocorticoid inhibition of fibroblast contraction of collagen gels. *Biochem Phatmacol* **35** : 1283-1286, 1986
- 35) Ehrlich HP, Wyler DJ : Fibroblast contraction of collagen lattice in vitro : inhibition by chronic inflammatory cell mediators. *J Cell Physiol* **116** : 345-351, 1983
- 36) Giri SN, Hyde DM, Marafino BJ Jr. : Ameliorating effect of murine interferon gamma on bleomycin-induced lung collagen fibrosis in mice. *Biochem Med Metab* **36** : 194-197, 1986
- 37) Kenyon AJ : Delayed wound-healing in mice associated with viral alteration of macrophages. *Am J Vet Res* **44** : 652-656, 1983